PERCEPTIVE INFORMATICS LAUNCHES THE NEXT LEVEL OF INTEGRATION IN ITS INDUSTRY-LEADING ECLINICAL SUITE
Boston, MA, June 22, 2009 – Bringing the next level of technology integration to clinical development, Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has launched its industry-leading eClinical Suite to provide truly seamless integration and access to data across multiple technologies throughout the trial process. A unique combination of Perceptive’s leading products and services, the suite is designed to realize the full potential of eClinical, yielding increased value and utility by creating an environment for more effective management and operation of clinical trials. The integrated suite features key components including the Perceptive Portal™, a combined Electronic Data Capture-Integrated Voice Response (EDC-IVR) solution, and a Clinical Technology Integration Platform (CTIP).
“More than ever, our customers need to make better, faster, and more informed decisions about their compounds in development. At Perceptive Informatics, we are delivering on our vision for eClinical by bringing increased value and technology innovation to meet critical customer needs to accelerate the clinical trial process,” said Steve Kent, President, Perceptive Informatics. “We expect our customers to benefit noticeably from this suite of integrated technologies and services that are aligned to help achieve their development goals.”
“In the past, clinical data were simply moved between applications to reduce the need to reconcile independent databases. Perceptive has made integration scalable by implementing cutting-edge integration middleware. This new level of integration is focused on simplifying processes to create highly optimized experiences for users. By enabling the core functionality of one solution to be accessed from another, this convergence of our solutions is a dramatic shift in the way that technologies can be used together to streamline workflow while facilitating more effective trial management,” said Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics.
The new components of Perceptive’s eClinical suite include:
- A Combined EDC-IVR Solution, which is a key component of Perceptive’s eClinical Suite. The solution allows users to perform real-time randomization and dispensation activities directly from within the DataLabs® EDC solution using new advanced functionality built into the DataLabs EDC and ClinPhone® Randomization and Trial Supply Management (RTSM) technologies.
- The Perceptive Portal, which is a powerful enterprise portal solution that provides trial communities with secure, central access to essential study documentation and materials. It enables the display of high level consolidated clinical trial metrics data drawn from Perceptive’s technologies including the IMPACT® Clinical Trial Management System (CTMS), DataLabs EDC solution, and ClinPhone RTSM.
- A Clinical Technology Integration Platform (CTIP), which is a middleware solution providing seamless, automated exchange of data across different systems without having to modify applications on connected systems. This proven middleware supports two-way, real-time data interchange and enables diverse clinical trial applications to work together synergistically.
The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes ClinPhone RTSM (Randomization and Trial Supply Management) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the new integrated solutions in Perceptive’s eClinical Suite visit www.perceptive.com.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has over 9,400 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC on May 8, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.